The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
LOKELMA (AstraZeneca Pty Ltd)
Product name
LOKELMA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
206 (255 working days)
Active ingredients
sodium zirconium cyclosilicate hydrate
Registration type
NCE/NBE
Indication
LOKELMA is indicated for the treatment of hyperkalaemia in adult patients.